{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T06:01:10Z","timestamp":1674540070610},"reference-count":58,"publisher":"Begell House","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Long Term Eff Med Implants"],"published-print":{"date-parts":[[2023]]},"abstract":"<p>Cancer is established as a major contributor to global burden as millions of deaths are reported every year. Advances in molecular, epidemiologic and clinical research have led to significant improvements in prevention, screening and treatment of tumors. The purpose of the study is to describe the progress of oncology clinical trials performed in Greece during the past decade and the obstacles that still need to be addressed in cancer research. A search was conducted in the public database EU Clinical Trials Register using the algorithm 'cancer AND Greece'. Results included relevant trials approved between 2010 and 2020. A total of 480 trials were approved for conduct in Greece from 2010 to 2020. The majority are multinational, phase III trials, exploring the efficacy and safety of agents in the management of lung cancer and multiple myeloma. A variety of small-molecules and monoclonal antibodies has and is being tested against key binding targets. Based on their promising effects on patients' responses and outcomes, many have been marketed for the treatment of several cancer types and are considered milestones in cancer discovery. It goes without saying that oncology research has made tremendous steps towards the development of potent and tolerable anticancer agents, with Greece having an active role. Current efforts focus on the use of alternative designs and tools aiming at further improving patients' survival and quality of life, while globalization of clinical research is also a matter of high importance.\n<\/p>","DOI":"10.1615\/jlongtermeffmedimplants.2022044793","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T18:27:02Z","timestamp":1665167222000},"page":"79-88","source":"Crossref","is-referenced-by-count":0,"title":["Oncology Clinical Trials in Greece: Progress in the Past Decade"],"prefix":"10.1615","volume":"33","author":[{"given":"Maria Eleni","family":"Ourailidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Tsirigoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Kotsira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Angelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gazouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios K.","family":"Filippou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"issue":"3","key":"1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H.","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcdb.2016.08.025","article-title":"Molecular heterogeneity in breast cancer: State of the science and implications for patient care","volume":"64","author":"Ellsworth R.E.","year":"2017","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/path.4212","article-title":"Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer","volume":"231","author":"Budinska E.","year":"2013","journal-title":"J Pathol"},{"issue":"4","key":"4","doi-asserted-by":"crossref","DOI":"10.7603\/s40681-015-0019-4","article-title":"An overview of targeted cancer therapy","volume":"5","author":"Padma V.V.","year":"2015","journal-title":"Biomedicine"},{"issue":"2","key":"5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/apjon.apjon_79_17","article-title":"Targeted therapy: Attacking cancer with molecular and immunological targeted agents","volume":"5","author":"Wilkes G.M.","year":"2018","journal-title":"Asia Pac J Oncol Nurs"},{"issue":"2","key":"6","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10074","article-title":"First-in-human phase 1 studies in oncology: The new challenge for investigative sites","volume":"3","author":"Salzberg M.","year":"2012","journal-title":"Rambam Maimonides Med J"},{"issue":"1","key":"7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung cancer 2020: Epidemiology, etiology, and prevention","volume":"41","author":"Bade B.C.","year":"2020","journal-title":"Clin Chest Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2017.07.002","article-title":"Breast cancer epidemiology, prevention, and screening","volume":"151","author":"Winters S.","year":"2017","journal-title":"Prog Mol Biol Transl Sci"},{"key":"9","unstructured":"International Agency for Research on Cancer [homepage on the Internet]. Accessed in October 2021. Available from: https:\/\/www.iarc.who.int\/."},{"key":"10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101929","article-title":"Multiple myeloma: Role of autologous transplantation","volume":"82","author":"Ntanasis-Stathopoulos I.","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"11","article-title":"The management and costs of multiple myeloma in greece: Mapping the local treatment pathway and associated resource use","volume":"19","author":"Siskou O.","year":"2016","journal-title":"Value Heal"},{"issue":"6","key":"12","article-title":"Epidemiology and etiology of leukemia and lymphoma","volume":"10","author":"Bispo Jab.","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/187152013804487272","article-title":"Sunlight vitamin D and skin cancer","volume":"13","author":"Mason R.S.","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"issue":"1","key":"14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJMsb2019760","article-title":"The rapid rise in cutaneous melanoma diagnoses","volume":"384","author":"Welch H.G.","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.mcna.2020.08.007","article-title":"Screening for prostate cancer","volume":"104","author":"Carlsson S.V.","year":"2020","journal-title":"Med Clin North Am"},{"issue":"1","key":"16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1871530320999200818134339","article-title":"MicroRNAs for diagnosis and treatment of colorectal cancer","volume":"21","author":"Mei H.","year":"2021","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"3","key":"17","doi-asserted-by":"crossref","DOI":"10.1111\/ecc.13397","article-title":"Factors contributing to time to diagnosis in symptomatic colorectal cancer: A scoping review","volume":"30","author":"Golding H.","year":"2021","journal-title":"Eur J Cancer Care"},{"key":"18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae?","volume":"9","author":"Nurgali K.","year":"2018","journal-title":"Front Pharmacol"},{"issue":"12","key":"19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nchembio840","article-title":"New approaches to molecular cancer therapeutics","volume":"2","author":"Collins I.","year":"2006","journal-title":"Nat Chem Biol"},{"key":"20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone L.","year":"2018","journal-title":"Front Pharmacol"},{"issue":"2","key":"21","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2011.192","article-title":"Tumor control versus adverse events with targeted anticancer therapies","volume":"9","author":"Keefe D.M.","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"22","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1158\/1078-0432.CCR-07-2218","article-title":"Proteasome inhibitors in cancer therapy: Lessons from the first decade","volume":"14","author":"Orlowski R.Z.","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"11","key":"23","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1535-7163.MCT-11-0433","article-title":"Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma","volume":"10","author":"Hideshima T.","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"24","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.31","article-title":"Carfilzomib-lenalidomide-dexamethasone vs. lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment","volume":"7","author":"Dimopoulos M.A.","year":"2017","journal-title":"Blood Cancer J"},{"issue":"7","key":"25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch E.E.","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ajco.13459","article-title":"Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma","volume":"17","author":"Bai Y.","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"27","article-title":"Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials","volume":"4","author":"Cheng Y.","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"28","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): A randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel J.F.","year":"2016","journal-title":"Lancet Haematol"},{"issue":"5","key":"29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1634\/theoncologist.2017-0644","article-title":"Panobinostat and multiple myeloma in 2018","volume":"23","author":"Yee A.J.","year":"2018","journal-title":"Oncologist"},{"issue":"2-3","key":"30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0163-7258(02)00179-1","article-title":"Protein kinases as targets for anticancer agents: From inhibitors to useful drugs","volume":"93","author":"Fabbro D.","year":"2002","journal-title":"Pharmacol Ther"},{"issue":"1","key":"31","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong L.","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"32","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause D.S.","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"33","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years","volume":"13","author":"Huang L.","year":"2001","journal-title":"J Hematol Oncol"},{"issue":"2","key":"34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1634\/theoncologist.2018-0072","article-title":"Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: Results of the large, single-arm, open-label phase IIIb CONSIGN study","volume":"24","author":"Van Cutsem E.","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"35","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"HELIOS investigators. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan A.","year":"2016","journal-title":"Lancet Oncol"},{"issue":"25","key":"36","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia","volume":"378","author":"Dimopoulos M.A.","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"37","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00280-015-2861-1","article-title":"Targeted therapy in cancer","volume":"76","author":"Tsimberidou A.M.","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"22","key":"38","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1002\/cncr.32392","article-title":"Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE","volume":"125","author":"Perez E.A.","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert C.","year":"2020","journal-title":"Nat Commun"},{"key":"40","first-page":"1","article-title":"Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: Patient selection and perspectives","volume":"8","author":"Somasundaram A.","year":"2017","journal-title":"Lung Cancer"},{"issue":"14","key":"41","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen R.","year":"2019","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEY-NOTE-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness B.","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"43","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G.","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"25","key":"44","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone D.P.","year":"2017","journal-title":"N Engl J Med"},{"key":"45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01804","article-title":"New strategies using antibody combinations to increase cancer treatment effectiveness","volume":"8","author":"Corraliza-Gorjon I.","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"46","doi-asserted-by":"crossref","DOI":"10.3390\/antib9030034","article-title":"Monoclonal antibodies in cancer therapy","volume":"9","author":"Zahavi D.","year":"2020","journal-title":"Antibodies"},{"issue":"1","key":"47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma","volume":"18","author":"Bommareddy P.K.","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"19","key":"48","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-20-1170","article-title":"Talimogene laherparepvec and pembrolizumab in recurrent or metastatic squamous cell carcinoma of the head and neck (MASTER-KEY-232): A multicenter, phase 1b study","volume":"26","author":"Harrington K.J.","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"10","key":"49","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.molonc.2015.10.018","article-title":"Tumor-infiltrating lymphocytes for the treatment of metastatic cancer","volume":"9","author":"Geukes Foppen M.H.","year":"2015","journal-title":"Mol Oncol"},{"issue":"5777","key":"50","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1126\/science.1126758","article-title":"The new era in cancer research","volume":"312","author":"Varmus H.","year":"2006","journal-title":"Science"},{"key":"51","doi-asserted-by":"publisher","first-page":"132","DOI":"10.14694\/EdBook_AM.2015.35.e132","article-title":"The global conduct of cancer clinical trials: Challenges and opportunities","volume":"35","author":"Barrios C.H.","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"52","first-page":"181","article-title":"State of cancer research around the globe","volume":"33","author":"Copur M.S.","year":"2019","journal-title":"Oncology"},{"issue":"3","key":"53","first-page":"34","article-title":"Intranasal drug delivery system: A glimpse to become maestro","volume":"1","author":"Upadhyay S.","year":"2011","journal-title":"J Appl Pharm Sci"},{"key":"54","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2019.961","article-title":"Innovative approaches for cancer treatment: Current perspectives and new challenges","volume":"13","author":"Pucci C.","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"55","article-title":"Recent advances in precision oncology research","volume":"2","author":"Bode A.M.","year":"2018","journal-title":"NPJ Precis Oncol"},{"key":"56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2019.01.001","article-title":"Innovation in oncology clinical trial design","volume":"74","author":"Verweij J.","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"57","first-page":"1","article-title":"Endpoints in oncology clinical trials","volume":"23","author":"Kilickap S.","year":"2018","journal-title":"J BUON"},{"issue":"11","key":"58","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41416-021-01495-7","article-title":"An urgent call to raise the bar in oncology","volume":"125","author":"Schnog J.B.","year":"2021","journal-title":"Br J Cancer"}],"container-title":["Journal of Long-Term Effects of Medical Implants"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/6a7659456c2505be\/JLT-44793.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T09:38:29Z","timestamp":1674466709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/1bef42082d7a0fdf,6bb40c771d6fb8c2,6a7659456c2505be.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1615\/jlongtermeffmedimplants.2022044793","relation":{},"ISSN":["1050-6934"],"issn-type":[{"value":"1050-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}